Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Reduction of brain kynurenic acid improves cognitive function.

Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, Hajos M, Williams GV, Castner SA.

J Neurosci. 2014 Aug 6;34(32):10592-602. doi: 10.1523/JNEUROSCI.1107-14.2014.

2.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
3.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

Helal CJ, Kang Z, Hou X, Pandit J, Chappie TA, Humphrey JM, Marr ES, Fennell KF, Chenard LK, Fox C, Schmidt CJ, Williams RD, Chapin DS, Siuciak J, Lebel L, Menniti F, Cianfrogna J, Fonseca KR, Nelson FR, O'Connor R, MacDougall M, McDowell L, Liras S.

J Med Chem. 2011 Jul 14;54(13):4536-47. doi: 10.1021/jm2001508. Epub 2011 Jun 8.

PMID:
21650160
4.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S.

J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k.

PMID:
19630403
5.

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE.

Biochem Pharmacol. 2009 Oct 1;78(7):813-24. doi: 10.1016/j.bcp.2009.05.033. Epub 2009 Jun 6.

PMID:
19501054
6.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
7.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
8.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN.

Psychopharmacology (Berl). 2008 Mar;197(1):115-26. Epub 2007 Dec 1.

PMID:
18060387
9.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR.

Neuropharmacology. 2007 Jul;53(1):113-24. Epub 2007 Apr 29.

PMID:
17559891
10.

Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Siuciak JA, McCarthy SA, Martin AN, Chapin DS, Stock J, Nadeau DM, Kantesaria S, Bryce-Pritt D, McLean S.

Psychopharmacology (Berl). 2007 Oct;194(2):185-95. Epub 2007 Jun 10.

PMID:
17558564
11.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, Chapin DS, McCarthy SA, Martin AN.

Psychopharmacology (Berl). 2007 Jun;192(3):415-24. Epub 2007 Mar 2.

PMID:
17333137
12.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA.

Neuropharmacology. 2007 Feb;52(2):279-90. Epub 2006 Sep 1.

PMID:
16949622
13.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
14.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):374-85. Epub 2006 Jun 12.

PMID:
16769090
15.

Teaching sacrospinous colpopexy.

Chapin DS.

Am J Obstet Gynecol. 1997 Dec;177(6):1330-6.

PMID:
9423732
16.

5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H- pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety.

Villalobos A, Butler TW, Chapin DS, Chen YL, DeMattos SB, Ives JL, Jones SB, Liston DR, Nagel AA, Nason DM, et al.

J Med Chem. 1995 Jul 21;38(15):2802-8.

PMID:
7636841
17.

Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase.

Villalobos A, Blake JF, Biggers CK, Butler TW, Chapin DS, Chen YL, Ives JL, Jones SB, Liston DR, Nagel AA, et al.

J Med Chem. 1994 Aug 19;37(17):2721-34.

PMID:
8064800
18.

Laparoscopically assisted vaginal hysterectomy in female-to-male transsexuals.

Chapin DS.

Plast Reconstr Surg. 1993 Apr;91(5):962. No abstract available.

PMID:
8460204
19.

Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice.

Nielsen JA, Chapin DS, Johnson JL Jr, Torgersen LK.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):185S-189S. doi: 10.1093/ajcn/55.1.185s.

PMID:
1728832
20.

Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.

Lowe JA 3rd, Archer RL, Chapin DS, Chen JB, Helweg D, Johnson JL, Koe BK, Lebel LA, Moore PF, Nielsen JA, et al.

J Med Chem. 1991 Feb;34(2):624-8.

PMID:
1995886
21.

Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.

Saccomano NA, Vinick FJ, Koe BK, Nielsen JA, Whalen WM, Meltz M, Phillips D, Thadieo PF, Jung S, Chapin DS, et al.

J Med Chem. 1991 Jan;34(1):291-8.

PMID:
1992129
22.

Exogenous tryptophan increases synthesis, storage, and intraneuronal metabolism of 5-hydroxytryptamine in the rat hypothalamus.

Lookingland KJ, Shannon NJ, Chapin DS, Moore KE.

J Neurochem. 1986 Jul;47(1):205-12.

PMID:
2423645
24.

The effects of continuous androgen secretion on the hypothalamic-pituitary axis in woman: evidence from a luteinized thecoma of the ovary.

Dunaif A, Scully RE, Andersen RN, Chapin DS, Crowley WF Jr.

J Clin Endocrinol Metab. 1984 Sep;59(3):389-93.

PMID:
6086692
26.

Immunity to antigens associated with primate C-type oncoviruses in pregnant women.

Hirsch MS, Kelly AP, Chapin DS, Fuller TC, Black PH, Kurth R.

Science. 1978 Mar 24;199(4335):1337-40.

PMID:
204010

Supplemental Content

Loading ...
Support Center